Since mutations of TP53 are an early event in lung tumorigenesis and believed to be preserved to maintain the malignant phenotype during tumor progression and metastatic spread [38], we hypothesized that CTCs recovered and expanded from early stage lung cancer patients should preserve TP53 mutations present in the primary patient tumor. The gene discussed is TP53; the disease is lung carcinoma.